However, only ~60% of patients treated with anti-TNF therapies show improvement,3 suggesting there are additional immune mediators critical to disease progression.4 While other cytokines, integrins, and molecules involved in immune signaling have been targeted with some success,4 the TNF superfamily of cytokines itself includes several other members that play important roles in modulating immune responses, suggesting they also could have potential to influence IBD development.5 The gene discussed is TNF; the disease is inflammatory bowel disease.